Burning Rock Biotech Ltd
BNR6.370USD
+0.700+12.35%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
57.51MCap. mercado
PérdidaP/E TTM
Más Datos de Burning Rock Biotech Ltd Compañía
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
Información de la empresa
Símbolo de cotizaciónBNR
Nombre de la empresaBurning Rock Biotech Ltd
Fecha de salida a bolsaJun 12, 2020
Director ejecutivoMr. Yusheng Han
Número de empleados674
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 12
DirecciónNo. 5 Xingdao Ring Road North
CiudadGUANGZHOU
Bolsa de valoresXetra
PaísChina
Código postal510005
Teléfono
Sitio Webhttps://www.brbiotech.com/
Símbolo de cotizaciónBNR
Fecha de salida a bolsaJun 12, 2020
Director ejecutivoMr. Yusheng Han
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Feng Deng
Mr. Feng Deng
Director
Director
--
--
Ms. Xiaozhi Hu
Ms. Xiaozhi Hu
Senior Director in Finance
Senior Director in Finance
--
--
Ms. Wendy Hayes, CPA
Ms. Wendy Hayes, CPA
Independent Director
Independent Director
--
--
Dr. Lisa (Licen) Xu
Dr. Lisa (Licen) Xu
Independent Director
Independent Director
--
--
Mr. Yusheng Han
Mr. Yusheng Han
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Dr. Zhihong (Joe) Zhang, Ph.D.
Dr. Zhihong (Joe) Zhang, Ph.D.
Chief Technology Officer, Director
Chief Technology Officer, Director
--
--
Mr. Gang Lu
Mr. Gang Lu
Director
Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Feng Deng
Mr. Feng Deng
Director
Director
--
--
Ms. Xiaozhi Hu
Ms. Xiaozhi Hu
Senior Director in Finance
Senior Director in Finance
--
--
Ms. Wendy Hayes, CPA
Ms. Wendy Hayes, CPA
Independent Director
Independent Director
--
--
Dr. Lisa (Licen) Xu
Dr. Lisa (Licen) Xu
Independent Director
Independent Director
--
--
Mr. Yusheng Han
Mr. Yusheng Han
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Dr. Zhihong (Joe) Zhang, Ph.D.
Dr. Zhihong (Joe) Zhang, Ph.D.
Chief Technology Officer, Director
Chief Technology Officer, Director
--
--
Desglose de ingresos
FY2019
FY2018
Sin datos
Por regiónCNY
Nombre
Ganancia
Proporción
China (Mainland)
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 13 de jun
Actualizado: vie., 13 de jun
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Northern Light Venture Capital
11.67%
Kynam Capital Management LP
11.01%
Lyfe Capital
9.23%
China Merchants Bank Co Ltd
5.12%
Lilly Asia Ventures
4.85%
Other
58.11%
Accionistas
Accionistas
Proporción
Northern Light Venture Capital
11.67%
Kynam Capital Management LP
11.01%
Lyfe Capital
9.23%
China Merchants Bank Co Ltd
5.12%
Lilly Asia Ventures
4.85%
Other
58.11%
Tipos de accionistas
Accionistas
Proporción
Private Equity
20.90%
Hedge Fund
12.92%
Investment Advisor/Hedge Fund
7.58%
Bank and Trust
5.13%
Venture Capital
4.85%
Sovereign Wealth Fund
4.49%
Corporation
3.92%
Investment Advisor
3.56%
Research Firm
0.45%
Other
36.20%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
59
5.76M
63.80%
+1.00M
2025Q1
66
5.77M
63.83%
+940.56K
2024Q4
74
5.50M
64.55%
+928.80K
2024Q3
93
5.26M
61.71%
+353.76K
2024Q2
109
5.27M
61.79%
+40.23K
2024Q1
122
5.30M
62.18%
-174.69K
2023Q4
137
5.24M
61.49%
-310.76K
2023Q3
208
5.51M
64.24%
-866.01K
2023Q2
220
5.57M
64.96%
-832.63K
2023Q1
226
5.60M
65.29%
-882.42K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Northern Light Venture Capital
1.05M
11.67%
--
--
Mar 31, 2025
Kynam Capital Management LP
994.88K
11.01%
--
--
Mar 31, 2025
Lyfe Capital
833.84K
9.23%
--
--
Mar 31, 2025
China Merchants Bank Co Ltd
462.99K
5.12%
--
--
Mar 31, 2025
Lilly Asia Ventures
438.42K
4.85%
+438.42K
--
Dec 31, 2023
GIC Private Limited
405.64K
4.49%
+405.64K
--
Dec 31, 2023
MFS Investment Management
367.00K
4.06%
-2.73K
-0.74%
Mar 31, 2025
Quantum Boundary Holdings Ltd
353.92K
3.92%
+350.62K
+10637.83%
Mar 31, 2025
Fidelity International
280.90K
3.11%
--
--
Mar 31, 2025
CRCM L.P.
226.29K
2.5%
-99.68K
-30.58%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Avantis Responsible Emerging Markets Equity ETF
0%
DFA Dimensional Emerging Markets Core Equity 2 ETF
0%
SPDR S&P Emerging Markets Small Cap ETF
0%
Avantis Responsible Emerging Markets Equity ETF
Proporción0%
DFA Dimensional Emerging Markets Core Equity 2 ETF
Proporción0%
SPDR S&P Emerging Markets Small Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
Fecha
Tipo
Relación
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
